Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: Tumor and microenvironment

Leukemia and Lymphoma

Volumn 49, Issue 9, 2008, Pages 1668-1680

  Hsi, Eric D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Biomarkers; Lymphoma and Hodgkin disease; Microenviroment; Prognosis; Prognostic markers

Indexed keywords

B CELL ACTIVATING FACTOR; BLEOMYCIN; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CD30 ANTIGEN; CYTOCHROME C; DACARBAZINE; DOXORUBICIN; FAS ANTIGEN; GLUTATHIONE TRANSFERASE P1; HLA A ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 10; INTERLEUKIN 6; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MLH1; PROTEIN P53; PROTEIN P60; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNINDEXED DRUG; VINCRISTINE;

APOPTOSIS; B CELL LYMPHOMA; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CLASSICAL HODGKIN LYMPHOMA; CLINICAL FEATURE; DISEASE FREE SURVIVAL; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY INFILTRATE; MICROENVIRONMENT; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REED STERNBERG CELL; REVIEW; T LYMPHOCYTE ACTIVATION;

HODGKIN DISEASE; HUMANS; INFLAMMATION; PROGNOSIS; REED-STERNBERG CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 52349091768     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802163339     Document Type: Review

References (138)

1. Hodgkin, T. On some morbid appearances of the absorbent glands and spleen. Medical Chirurgical Trnasaction, 17, pp. 68-114.
2. Wilks, S. Cases of lardaceous disease and some allied affections, with remark. Guys Hsop Rep, 17, pp. 103-132.
3. Wilks, S. Cases with enlargement of the lymphatic glands and spleen (or Hodking's disease), with remarks. Guy's Hosp Rep, 11, pp. 56-67.
4. Greenfield, W. S. Specimens illustrative of the pathology of lymphadenoma and leucocythemia. Trans Path Soc London, 29, pp. 272-304.
5. Langerhans, T. Das milgne lymphosarkom (pseudoleukamie). Virchow's Archiv f path Anatomie, 54, pp. 509-537.
6. Reed, D. M. (1902) On the pathological changes in Hodgkin's disease, with special reference to its relation to tuberculosis. Johns Hopkins Hosp Rep, 10, pp. 133-196.
7. Sternberg, C. Uber eine eigenartige unter dem Bilde der Psuedoleukamie verlaufende Tuberculose des lymphatische Apparates. Ztschr Heilk, 19, pp. 21-90.
8. Fox, H. (1926) Remarks on the microscopical preparations made form some of the original tissue described by Thomas Hodgkin 1832. Ann Med Hist, pp. 370-374.
9. Kaplan, H. S. (1980) Hodgkin's disease: Unfolding concepts concerning its nature, management and prognosis. Cancer, 45, pp. 2439-2474.
10. Harris, N. L., Jaffe, E. S. Stein, H. et al. (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group [see comments]. [Review][296 refs]. Blood, 84, pp. 1361-1392.
11. (2001) Tumours of Haematopoeitic and Lymphoid Tissues, IARC Press, Lyon
12. Hummel, M., Ziemann, K. Lammert, H. et al. (1995) Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells [see comments]. New Engl J Med, 333, pp. 901-906.
13. Marafioti, T., Hummel, M. Foss, H. D. et al. (2000) Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood, 95, pp. 1443-1450.
14. Delabie, J., Tierens, A. Gavriil, T. et al. (1996) Phenotype, genotype and clonality of Reed-Sternberg cells in nodular sclerosis Hodgkin's disease: Results of a single-cell study. Br J Haematol, 94, pp. 198-205.
15. Kanzler, H., Kuppers, R., Hansmann, M. L. and Rajewsky, K. (1996) Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med, 184, pp. 1495-1505.
16. Kuppers, R., Rajewsky, K. Zhao, M. et al. (1994) Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA, 91, pp. 10962-10966.
17. Diehl, V., Stein, H., Hummel, M., Zollinger, R. and Connors, J. M. (2003) Hodgkin's Lymphoma: Biology and treatment strategies for primary, refractory, and relapsed DISEASE. Hematology (Am Soc Hematol Educ Program), pp. 225-247.
18. Krappmann, D., Emmerich, F. Kordes, U. et al. (1999) Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/ Reed-Sternberg cells. Oncogene, 18, pp. 943-953.
19. Thomas, R. K., Re, D., Wolf, J. and Diehl, V. (2004) Part I: Hodgkin's lymphoma-molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol, 5, pp. 11-18.
20. Re, D., Hofmann, A., Wolf, J., Diehl, V. and Staratschek-Jox, A. (2000) Cultivated H-RS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95. Exp Hematol, 28, pp. 31-35.
21. Maggio, E. M., van den, B. A., de Jong, D., Diepstra, A. and Poppema, S. (2003) Low frequency of FAS mutations in Reed-Sternberg cells of Hodgkin's lymphoma. Am J Pathol, 162, pp. 29-35.
22. Muschen, M., Re, D. Brauninger, A. et al. (2000) Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Res, 60, pp. 5640-5643.
23. Thomas, R. K., Kallenborn, A. Wickenhauser, C. et al. (2002) Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am J Pathol, 160, pp. 1521-1528.
24. Dutton, A., O'Neil, J. D. Milner, A. E. et al. (2004) Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc Natl Acad Sci USA, 101, pp. 6611-6616.
25. Mathas, S., Lietz, A. Anagnostopoulos, I. et al. (2004) c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med, 199, pp. 1041-1052.
26. Kashkar, H., Haefs, C. Shin, H. et al. (2003) XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells. J Exp Med, 198, pp. 341-347.
27. Kim, L. H., Nadarajah, V. S., Peh, S. C. and Poppema, S. (2004) Expression of Bcl-2 family members and presence of Epstein-Barr virus in the regulation of cell growth and death in classical Hodgkin's lymphoma. Histopathology, 44, pp. 257-267.
28. van Spronsen, D. J., Peh, S. C., Vrints, L. W., van Imhoff, G. W. and Poppema, S. (2000) Clinical drug-resistant nodular sclerosing Hodgkin's lymphoma is associated with decreased bcl-2 expression in the surrounding lymphocytes and with increased bcl-2 expression in the Reed-Sternberg cells. Histopathology, 37, pp. 420-426.
29. Chu, W. S., Aguilera, N. S., Wei, M. Q. and Abbondanzo, S. L. (1999) Antiapoptotic marker Bcl-X(L), expression on Reed-Sternberg cells of Hodgkin's disease using a novel monoclonal marker, YTH-2H12. Hum Pathol, 30, pp. 1065-1070.
30. Hell, K., Lorenzen, J., Fischer, R. and Hansmann, M. L. (1995) Hodgkin cells accumulate mRNA for bcl-2. Lab Invest, 73, pp. 492-496.
31. Sup, S. J., Alemany, C. A. Pohlman, B. et al. (2005) Expression of bcl-2 in classical Hodgkin's lymphoma: An independent predictor of poor outcome. J Clin Oncol, 23, pp. 3773-3779.
32. Kucharczak, J., Simmons, M. J., Fan, Y. and Gelinas, C. (2003) To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene, 22, pp. 8961-8982.
33. Rayet, B. and Gelinas, C. (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene, 18, pp. 6938-6947.
34. Bargou, R. C., Emmerich, F. Krappmann, D. et al. (1997) Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest, 100, pp. 2961-2969.
35. Hinz, M., Loser, P. Mathas, S. et al. (2001) Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood, 97, pp. 2798-2807.
36. Izban, K. F., Ergin, M. Huang, Q. et al. (2001) Characterization of NF-kappaB expression in Hodgkin's disease: Inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Mod Pathol, 14, pp. 297-310.
37. Zhao, X., Qiu, W. Kung, J. et al. (2007) Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: A gene expression profiling study with implications for potential combination therapies. Leuk Res
38. Carbone, A., Gloghini, A., Gruss, H. J. and Pinto, A. (1995) CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol, 147, pp. 912-922.
39. Carbone, A., Gloghini, A. Gattei, V. et al. (1995) Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood, 85, pp. 780-789.
40. Emmerich, F., Meiser, M. Hummel, M. et al. (1999) Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood, 94, pp. 3129-3134.
41. Fiumara, P., Snell, V. Li, Y. et al. (2001) Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood, 98, pp. 2784-2790.
42. Cabannes, E., Khan, G., Aillet, F., Jarrett, R. F. and Hay, R. T. (1999) Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene, 18, pp. 3063-3070.
43. Wood, K. M., Roff, M. and Hay, R. T. (1998) Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB. Oncogene, 16, pp. 2131-2139.
44. Herbst, H. (1996) Epstein-Barr virus in Hodgkin's disease. Semin Cancer Biol, 7, pp. 183-189.
45. Bechtel, D., Kurth, J., Unkel, C. and Kuppers, R. (2005) Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. Blood, 106, pp. 4345-4350.
46. Chaganti, S., Bell, A. I. Pastor, N. B. et al. (2005) Epstein-Barr virus infection in vitro can rescue germinal center B cells with inactivated immunoglobulin genes. Blood, 106, pp. 4249-4252.
47. Mancao, C., Altmann, M., Jungnickel, B. and Hammerschmidt, W. (2005) Rescue of "crippled" germinal center B cells from apoptosis by Epstein-Barr virus. Blood, 106, pp. 4339-4344.
48. Gires, O., Zimber-Strobl, U. Gonnella, R. et al. (1997) Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J, 16, pp. 6131-6140.
49. Caldwell, R. G., Wilson, J. B., Anderson, S. J. and Longnecker, R. (1998) Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity, 9, pp. 405-411.
50. Maggio, E., van den, B. A. Diepstra, A. et al. (2002) Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol, 13, pp. 52-56.
51. Poppema, S. (2005) Immunobiology and pathophysiology of hodgkin lymphomas. Hematology (Am Soc Hematol Educ Program), pp. 231-238.
52. Chiu, A., Xu, W. He, B. et al. (2007) Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood, 109, pp. 729-739.
53. Hanamoto, H., Nakayama, T. Miyazato, H. et al. (2004) Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells. Am J Pathol, 164, pp. 997-1006.
54. Skinnider, B. F. and Mak, T. W. (2002) The role of cytokines in classical Hodgkin lymphoma. Blood, 99, pp. 4283-4297.
55. Skinnider, B. F., Kapp, U. and Mak, T. W. (2002) The role of interleukin 13 in classical Hodgkin lymphoma. Leuk Lymphoma, 43, pp. 1203-1210.
56. Juszczynski, P., Ouyang, J. Monti, S. et al. (2007) The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA, 104, pp. 13134-13139.
57. Jundt, F., Anagnostopoulos, I. Bommert, K. et al. (1999) Hodgkin/ Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood, 94, pp. 2065-2071.
58. Yamamoto, R., Nishikori, M. Kitawaki, T. et al. (2008) PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood, 111, pp. 3220-3224.
59. Fischer, M., Juremalm, M. Olsson, N. et al. (2003) Expression of CCL5/ RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer, 107, pp. 197-201.
60. Glimelius, I., Edstrom, A. Amini, R. M. et al. (2006) IL-9 expression contributes to the cellular composition in Hodgkin lymphoma. Eur J Haematol, 76, pp. 278-283.
61. Molin, D., Fischer, M. Xiang, Z. et al. (2001) Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol, 114, pp. 616-623.
62. Hasenclever, D. and Diehl, V. (1998) A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease N Engl J Med, 339, pp. 1506-1514.
63. Casasnovas, R. O., Mounier, N. Brice, P. et al. (2007) Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: A study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 25, pp. 1732-1740.
64. Gause, A., Pohl, C. Tschiersch, A. et al. (1991) Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood, 77, pp. 1983-1988.
65. Gause, A., Jung, W. Schmits, R. et al. (1992) Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma. Ann Oncol, 3, pp. 49-52.
66. Gause, A., Jung, W. Keymis, S. et al. (1992) The clinical significance of cytokines and soluble forms of membrane-derived activation antigens in the serum of patients with Hodgkin's disease. Leuk Lymphoma, 7, pp. 439-447.
67. Nadali, G., Vinante, F. Ambrosetti, A. et al. (1994) Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol, 12, pp. 793-797.
68. Visco, C., Nadali, G. Vassilakopoulos, T. P. et al. (2006) Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol, 77, pp. 387-394.
69. Zanotti, R., Trolese, A. Ambrosetti, A. et al. (2002) Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. Ann Oncol, 13, pp. 1908-1914.
70. Axdorph, U., Sjoberg, J. Grimfors, G. et al. (2000) Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease. Ann Oncol, 11, pp. 1405-1411.
71. Herbst, H., Foss, H. D. Samol, J. et al. (1996) Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood, 87, pp. 2918-2929.
72. Marshall, N. A., Christie, L. E. Munro, L. R. et al. (2004) Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood, 103, pp. 1755-1762.
73. Bohlen, H., Kessler, M., Sextro, M., Diehl, V. and Tesch, H. (2000) Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol, 79, pp. 110-113.
74. Salgami, E. V., Efstathiou, S. P. Vlachakis, V. et al. (2002) High pretreatment interleukin-10 is an independent predictor of poor failure-free survival in patients with Hodgkin's lymphoma. Haematologia (Budap), 32, pp. 377-387.
75. Sarris, A. H., Kliche, K. O. Pethambaram, P. et al. (1999) Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol, 10, pp. 433-440.
76. Vassilakopoulos, T. P., Nadali, G. Angelopoulou, M. K. et al. (2001) Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica, 86, pp. 274-281.
77. Visco, C., Vassilakopoulos, T. P. Kliche, K. O. et al. (2004) Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. Leuk Lymphoma, 45, pp. 2085-2092.
78. Viviani, S., Notti, P. Bonfante, V. et al. (2000) Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experience. Med Oncol, 17, pp. 59-63.
79. Gorschluter, M., Bohlen, H., Hasenclever, D., Diehl, V. and Tesch, H. (1995) Serum cytokine levels correlate with clinical parameters in Hodgkin's disease. Ann Oncol, 6, pp. 477-482.
80. Gruss, H. J., Dolken, G., Brach, M. A., Mertelsmann, R. and Herrmann, F. (1993) The significance of serum levels of soluble 60kDa receptors for tumor necrosis factor in patients with Hodgkin's disease. Leukemia, 7, pp. 1339-1343.
81. Trumper, L., Jung, W. Dahl, G. et al. (1994) Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease. Ann Oncol, 5, pp. 93-96.
82. Vener, C., Guffanti, A. Pomati, M. et al. (2000) Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis. Leuk Lymphoma, 37, pp. 333-339.
83. Warzocha, K., Bienvenu, J. Ribeiro, P. et al. (1998) Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. Br J Cancer, 77, pp. 2357-2362.
84. Clodi, K. and Younes, A. (1997) Reed-Sternberg cells and the TNF family of receptors/ligands. Leuk Lymphoma, 27, pp. 195-205.
85. Oki, Y., Georgakis, G. V., Migone, T. S., Kwak, L. W. and Younes, A. (2007) Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma. Haematologica, 92, pp. 269-270.
86. Tecchio, C., Nadali, G. Scapini, P. et al. (2007) High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma. Br J Haematol, 137, pp. 553-559.
87. Peh, S. C., Kim, L. H. and Poppema, S. (2001) TARC, a CC chemokine, is frequently expressed in classic Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma. Am J Surg Pathol, 25, pp. 925-929.
88. van den Berg, A., Visser, L. and Poppema, S. (1999) High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol, 154, pp. 1685-1691.
89. Ma, Y., Visser, L. Roelofsen, H. et al. (2008) Proteomics analysis of Hodgkin lymphoma: Identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood, 111, pp. 2339-2346.
90. Niens, M., Visser, L. Nolte, I. M. et al. (2008) Serum chemokine levels in Hodgkin lymphoma patients: Highly increased levels of CCL17 and CCL22. Br J Haematol, 140, pp. 527-536.
91. Weihrauch, M. R., Manzke, O. Beyer, M. et al. (2005) Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: Potential for a prognostic factor. Cancer Res, 65, pp. 5516-5519.
92. Cordano, P., Lake, A. Shield, L. et al. (2005) Effect of IL-6 promoter polymorphism on incidence and outcome in Hodgkin's lymphoma. Br J Haematol, 128, pp. 493-495.
93. Cozen, W., Gill, P. S. Ingles, S. A. et al. (2004) IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood 103, pp. 3216-3221.
94. Cozen, W., Gill, P. S. Salam, M. T. et al. (2008) Interleukin-2, interleukin-12 and interferon-{gamma} levels and risk of young adult Hodgkin lymphoma. Blood, 111, pp. 3377-3382.
95. da Silva, G. N., Bacchi, M. M., Rainho, C. A. and de Oliveira, D. E. (2007) Epstein-Barr virus infection and single nucleotide polymorphisms in the promoter region of interleukin 10 gene in patients with Hodgkin lymphoma. Arch Pathol Lab Med, 131, pp. 1691-1696.
96. Hohaus, S., Giachelia, M. Di Febo, A et al. (2007) Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol, 18, pp. 1376-1381.
97. Kelly, K. M. and Perentesis, J. P. (2002) Polymorphisms of drug metabolizing enzymes and markers of genotoxicity to identify patients with Hodgkin's lymphoma at risk of treatment-related complications. Ann Oncol, 13, pp. 34-39.
98. Knecht, H., Bachmann, E. Joske, D. J. et al. (1993) Molecular analysis of the LMP (latent membrane protein) oncogene in Hodgkin's disease. Leukemia, 7, pp. 580-585.
99. Lin, J. C., Lin, S. C., Luppi, M., Torelli, G. and Mar, E. C. (1995) Geographic sequence variation of latent membrane protein 1 gene of Epstein-Barr virus in Hodgkin's lymphomas. J Med Virol, 45, pp. 183-191.
100. Niens, M., Jarrett, R. F. Hepkema, B. et al. (2007) HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+Hodgkin lymphoma. Blood, 110, pp. 3310-3315.
101. Niens, M., van den, B. A. Diepstra, A. et al. (2006) The human leukocyte antigen class I region is associated with EBV-positive Hodgkin's lymphoma: HLA-A and HLA complex group 9 are putative candidate genes. Cancer Epidemiol Biomarkers Prev, 15, pp. 2280-2284.
102. Wihlborg, C., Sjoberg, J. Intaglietta, M. et al. (1999) Tumour necrosis factor-alpha cytokine promoter gene polymorphism in Hodgkin's disease and chronic lymphocytic leukaemia. Br J Haematol, 104, pp. 346-349.
103. Worrillow, L., Smith, A. Scott, K. et al. (2008) Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. J Med Genet, 45, pp. 142-146.
104. Zhou, X. G., Sandvej, K. Li, P. J. et al. (2001) Epstein-Barr virus gene polymorphisms in Chinese Hodgkin's disease cases and healthy donors: identification of three distinct virus variants. J Gen Virol, 82, pp. 1157-1167.
105. Hohaus, S., Di Ruscio, A Di Febo, A et al. (2005) Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin Cancer Res, 11, pp. 2175-2179.
106. Brink, A. A., Oudejans, J. J. van den Brule, A J et al. (1998) Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: Involvement of apoptosis resistance?. Mod Pathol, 11, pp. 376-383.
107. Jakovic, L. R., Mihaljevic, B. S. Jovanovic, M. D. et al. (2007) The expression of Ki-67 and Bcl-2 in Hodgkin's lymphoma: Correlation with the International Prognostic Score and bulky disease: A study by the Serbian Lymphoma Study Group (SLG). Med Oncol, 24, pp. 45-53.
108. Montalban, C., Garcia, J. F. Abraira, V. et al. (2004) Influence of biologic markers on the outcome of Hodgkin's lymphoma: A study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol, 22, pp. 1664-1673.
109. Rassidakis, G. Z., Medeiros, L. J. McDonnell, T. J. et al. (2002) BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome. Clin Cancer Res, 8, pp. 488-493.
110. Rassidakis, G. Z., Medeiros, L. J. Vassilakopoulos, T. P. et al. (2002) BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood, 100, pp. 3935-3941.
111. Smolewski, P., Robak, T. Krykowski, E. et al. (2000) Prognostic factors in Hodgkin's disease: Multivariate analysis of 327 patients from a single institution. Clin Cancer Res, 6, pp. 1150-1160.
112. Vassallo, J., Metze, K., Traina, F., de Souza, C. A. and Lorand-Metze, I. (2003) The prognostic relevance of apoptosis-related proteins in classical Hodgkin's lymphomas. Leuk Lymphoma, 44, pp. 483-488.
113. Sanchez-Aguilera, A., Montalban, C. de la, C. P. et al. (2006) Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood, 108, pp. 662-668.
114. Provencio, M., Corbacho, C. Salas, C. et al. (2003) The topoisomerase IIalpha expression correlates with survival in patients with advanced Hodgkin's lymphoma. Clin Cancer Res, 9, pp. 1406-1411.
115. Hsi, E. D., Sup, S. J. Alemany, C. et al. (2006) MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis. Am J Clin Pathol, 125, pp. 776-782.
116. Portlock, C. S., Donnelly, G. B. Qin, J. et al. (2004) Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. Br J Haematol, 125, pp. 701-708.
117. Tzankov, A., Krugmann, J. Fend, F. et al. (2003) Prognostic significance of CD20 expression in classical Hodgkin lymphoma: A clinicopathological study of 119 cases. Clin Cancer Res, 9, pp. 1381-1386.
118. Valsami, S., Pappa, V. Rontogianni, D. et al. (2007) A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: A potential prognostic role of MUM1/IRF4. Haematologica, 92, pp. 1343-1350.
119. Alvaro-Naranjo, T., Lejeune, M. Salvado-Usach, M. T. et al. (2005) Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: A quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma, 46, pp. 1581-1591.
120. Alvaro, T., Lejeune, M. Salvado, M. T. et al. (2005) Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res, 11, pp. 1467-1473.
121. Asano, N., Oshiro, A. Matsuo, K. et al. (2006) Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: A clinicopathologic study. J Clin Oncol, 24, pp. 4626-4633.
122. Baur, A. S., Meuge-Moraw, C., Michel, G. and Delacretaz, F. (1998) Prognostic value of follicular dendritic cells in nodular sclerosing Hodgkin's disease. Histopathology, 32, pp. 512-520.
123. Camilleri-Broet, S., Ferme, C. Berger, F. et al. (2004) TiA1 in advanced-stage classical Hodgkin's lymphoma: No prognostic impact for positive tumour cells or number of cytotoxic cells. Virchows Arch, 445, pp. 344-346.
124. Diepstra, A., van Imhoff, G. W. Karim-Kos, H. E. et al. (2007) HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol, 25, pp. 3101-3108.
125. Molin, D., Edstrom, A. Glimelius, I. et al. (2002) Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol, 119, pp. 122-124.
126. Oudejans, J. J., Jiwa, N. M. Kummer, J. A. et al. (1997) Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood, 89, pp. 1376-1382.
127. Kelley, T. W., Pohlman, B., Elson, P. and Hsi, E. D. (2007) The ratio of FOXP3+regulatory T cells to granzyme B+cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol, 128, pp. 958-965.
128. Morente, M. M., Piris, M. A. Abraira, V. et al. (1997) Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood, 90, pp. 2429-2436.
129. Spector, N., Milito, C. B. Biasoli, I. et al. (2005) The prognostic value of the expression of Bcl-2, p53 and LMP-1 in patients with Hodgkin's lymphoma. Leuk Lymphoma, 46, pp. 1301-1306.
130. Xerri, L., Bouabdallah, R., Camerlo, J. and Hassoun, J. (1994) Expression of the p53 gene in Hodgkin's disease: Dissociation between immunohistochemistry and clinicopathological data. Hum Pathol, 25, pp. 449-454.
131. Smolewski, P., Niewiadomska, H., Los, E. and Robak, T. (2000) Spontaneous apoptosis of Reed-Sternberg and Hodgkin cells; clinical and pathological implications in patients with Hodgkin's disease. Int J Oncol, 17, pp. 603-609.
132. Benharroch, D., Levy, A. Prinsloo, I. et al. (1999) Apoptotic index as a prognostic factor in Hodgkin's disease. Leuk Lymphoma, 33, pp. 351-359.
133. Dukers, D. F., Meijer, C. J. ten Berge, R L et al. (2002) High numbers of active caspase 3-positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome. Blood, 100, pp. 36-42.
134. Smolewski, P., Niewiadomska, H., Blonski, J. Z., Robak, T. and Krykowski, E. (1998) Expression of proliferating cell nuclear antigen (PCNA) and p53, bcl-2 or C-erb B-2 proteins on Reed-Sternberg cells: prognostic significance in Hodgkin's disease. Neoplasma, 45, pp. 140-147.
135. Garcia, J. F., Camacho, F. I. Morente, M. et al. (2003) Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: Analyses using tissue microarrays. Blood, 101, pp. 681-689.
136. Savage, K. J., Monti, S. Kutok, J. L. et al. (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood, 102, pp. 3871-3879.
137. Alonso, M. A. and Millan, J. (2001) The role of lipid rafts in signalling and membrane trafficking in T lymphocytes. J Cell Sci, 114, pp. 3957-3965.
138. Copie-Bergman, C., Plonquet, A. Alonso, M. A. et al. (2002) MAL expression in lymphoid cells: Further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol, 15, pp. 1172-1180.